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a b s t r a c t
This study reports the development of nanoemulsions intended for intravenous administration of thalido-
mide (THD). The formulations were prepared by spontaneous emulsiﬁcation method and optimized
with respect to thalidomide (0.01–0.05%, w/w), and hydrophilic emulsiﬁer (polysorbate 80; 0.5–4.0%,
w/w) content. The formulations were evaluated concerning physical appearance and drug crystalliza-
tion; droplet size; zeta potential and drug assay. Only the formulation containing 0.01% THD and 0.5%
polysorbate kept its properties in a satisfactory range over the evaluated period (60 days), i.e. droplet
size around 200nm, drug content around 95% and zeta potential around −30mV. The transmission elec-
tron microscopy revealed emulsion droplets almost spherical in shape conﬁrming the results obtained
by photon correlation spectroscopy. Drug crystallization observed for higher content (THD 0.05%, w/w)
nanoemulsionswas investigated. The crystals observed at opticalmicroscopypresented adifferent crystal
habit compared to that of the raw material used. It was speculated whether the kind of THD polymorph
employed could inﬂuence nanoemulsion formulation. Formulations were prepared with either one of
THD polymorphs (- or-) and crystals were characterized by fourier transformed infrared spectroscopy
(FTIR) and X-ray diffraction (XRD). It was observed that regardless of the polymorph employed (- or-),
drug crystallization occurs in the -form. THD solubility in oils was not inﬂuenced by the polymorphic
form. In addition, the in vitro dissolution proﬁle of the selected formulation (THD0.01%,w/w; polysorbate
0.5%, w/w) was assessed by bulk-equilibrium reverse dialysis sac technique and demonstrated a release
proﬁle similar to that of a THD acetonitrile solution, with around 95% THD being dissolved within 4h.
Finally, a pharmacokinetic simulation of an intravenous infusion of 250mL of the selected nanoemulsion
suggests that the parenteral administration of a dose as low as 25mg might lead to therapeutic plasma
ide.
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. Introduction
Thalidomide (THD) is a glutamic acid derivativewhichwas used
uring 1960s as a nonbarbiturate sedative agent. It was withdrawn
ue to toxic effects such as a teratogenicity and neuropathy. Cur-
ently, the FDA approved its use for the management of the acute
utaneous manifestations of erythema nodosum leprosum or pre-
ention of recurrences (type II) and multiple myeloma (Eriksson
t al., 2001;Teoet al., 2004;Zeldis et al., 1999).During the last years,
HDhasbeen found to exhibit pharmacologic effectswhich suggest
ts use for the treatment of aphthous ulcers, sepsis, Behcet’s disease
nd somechronicdegenerativediseases (like graft-versus-host dis-
ase (GVHD) and Lupus). Intravenous administration could be an
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lternative way to make THD available to patients with impaired
astrointestinal function like ulcerations in the upper tract (HIV
atients), poor intestinal absorption (GVHD) and coma. However,
ts lowaqueous solubility and lowstability impair thedevelopment
f a parenteral formulation, which would be of clinical interest for
hese patients (Schmidt et al., 1996; Jacobson et al., 1999; Eriksson
t al., 2001; Teo et al., 2004; Vogelsang and Higman, 2004).
Some pharmaceutical strategies have been described to
nhance stability and solubility of THD, such as its complexa-
ion with hydroxypropyl--cyclodextrin (Krenn et al., 1992), the
ttempt to use the pure enantiomeric forms (Eriksson et al., 2000)
s well as its association to polymeric carriers (Chen et al., 2008).
Open access under the Elsevier OA license.Submicron emulsions, known as nanoemulsions, have been
sed for years for parenteral nutrition and drug delivery due to
heir biocompatibility, relative stability, ability to solubilize high
uantities of hydrophobic compounds, ability to reduce the toxic-
ty of cytotoxic drugs and ability to protect drugs from hydrolysis
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Table 1
Final composition of nanoemulsions.
Test Formulations % (w/w)
THD Castor oil Soybean lecithin Polysorbate 80 Water q.s.p.
THD 0.01 0.01 10 3.0 – 100
THD 0.015 0.015 10 3.0 – 100
THD 0.02 0.02 10 3.0 – 100
THD 0.05 0.05 10 3.0 – 100
THD 0.01P0.5 0.01 10 3.0 0.5 100
THD 0.01P1.0 0.01 10 3.0 1.0 100
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THD 0.01P4.0 0.01 10
HD: Thalidomide; THD 0.01PX: Thalidomide 0.01% and X% of polysorbate.
nd enzymatic degradation in physiologic conditions (Benita and
evy, 1993; Klang and Benita, 1998; Han et al., 2004; Waitzberg et
l., 2006).
In this context, nanoemulsions seem to be an interesting dosage
orm for intravenous administration of THD. Therefore, the aim of
his studywas to investigate the feasibility of producingnanoemul-
ions for thalidomide parenteral delivery.
. Materials and methods
.1. Materials and reagents
Thalidomide reference standard (RS) (99%) and raw material
- and -polymorphic forms) (Microbiologica) were generously
ifted by Fundac¸ão Ezequiel Dias (Minas Gerais, Brazil). In all cases,
halidomide was a racemic mixture, which consists of equimolar
mount of (+)-(R)- and (−)-(S)-thalidomide. Ultrapure water was
btained from a Milli-Q® Plus apparatus (Millipore, Billerica, USA).
cetonitrile and methanol HPLC grade were purchased from CER
rasil (São Paulo, Brazil) and Tedia (Rio de Janeiro, Brazil), respec-
ively.Oliveoil, soybeanoil andsoybean lecithin (LipoidS75®)were
indly gifted by Lipoid GmbH (Ludwigshafen, Germany); puriﬁed
astor oil was purchased from Sigma Aldrich (Seelze, Germany),
olysorbate 80was kindly donated byCroda (Campinas, Brazil) and
lycerol was purchased from Nuclear (São Paulo, Brazil). All other
hemicals and reagents were of analytical or HPLC grade.
.2. High-performance liquid chromatographic analysis
Analysis were performed in an HPLC system Prominence,
hich consisted of a DGU-20A5 degasser, LC-20 AT pumps,
SIL-20 A autosampler, a SPD-20AV UV/Vis detector (set at
00nm), a CBM-20A communication bus module and LC solu-
ion software, version 1.24 SP1 (Schimadzu, Corporation). The
ethod employed a Shimadzu® LC Shim-pack CLC-ODS (M)
.6mm×25 cm (250×4.6mm d.i.) column, injection volume of
0L, and mobile phase composed of acetonitrile:ammonium
cetate buffer (pH 5.5; 10mM) (45:55, v/v) under an isocratic ﬂow
f 1.0mL/min. This method was previously validated according
o ICH Guidelines (ICH-Q2 (R1), 2005) and proved speciﬁc, linear
r2 >0.9998), precise (R.S.D. < 1.33%), accurate (recovery from 99.8
o 100.3%) and robust (Araújo, 2010).
.3. Determination of THD solubility in different oils
For determination of THD solubility in different oils, excess
mounts of THD were added to castor oil; medium chain triglyc-
rides (MCT); olive oil; soybean oil; and themixture castor oil:MCT
1:1) in sealed vials (in triplicate). The vials were kept under
onstant magnetic stirring at room temperature during 24h. The
ample was centrifuged at 15,000 rpm for 120min at 20 ◦C, an
u
I
2
s3.0 2.0 100
3.0 4.0 100
liquot of the supernatant was diluted with a diluent solution
omposed of acetonitrile and ammonium acetate buffer (pH 5.5;
0mM) (90:10, v/v) and THD content was assayed by HPLC. The
olubility of both THD polymorphs (- or -) was investigated.
.4. THD nanoemulsions preparation
The nanoemulsions were prepared by spontaneous emulsiﬁca-
ion (Yu et al., 1993; Bouchemal et al., 2004). Brieﬂy, the organic
hase consisting of absolute ethanol, oil (castor oil, 10.0%, w/w),
ipophilic emulsiﬁer (soybean lecithin, 3.0%, w/w) and THD (-
olymorphic form)previouslyhomogenized,were injected into the
queous phase consisting of water, osmotic agent (glycerol, 2.25%,
/w) and a hydrophilic emulsiﬁer (polysorbate 80), under mag-
etic stirring. The magnetic stirring was maintained during 30min
o allow the system to reach equilibrium. The solvent proportion
as 1/2, ethanol/water. Ethanol and excesswaterwere removedby
vaporation under reduced pressure until a volume of 10mL was
eached. The pH was adjusted to 5.0–5.5 with HCl 0.01M. A ﬁrst
et of formulations was prepared with different concentrations of
halidomide (0.01, 0.015, 0.02 and 0.05%, w/w) and no hydrophilic
mulsiﬁer and named THD 0.01; THD 0.015; THD 0.02, and THD
.05, accordingly. Afterwards, another set of formulationswasopti-
ized with respect to the polysorbate 80 content (0.5, 1.0, 2.0 and
.0%, w/w) and named THD 0.01P0.5; THD 0.01P1.0; THD 0.01P2.0,
nd THD 0.01P4.0. Blank formulations were also prepared. Formu-
ations composition is presented in Table 1.
.5. Characterization of THD nanoemulsions
The formulations were stored at 4 ◦C and monitored with
espect to physical appearance and formation of THD crystals,
article size, zetapotential aswell asdrug content. The selected for-
ulation was evaluated regarding these parameters plus viscosity
nd morphology.
.5.1. Particle size analysis
The mean particle size and polydispersity index were mea-
ured at 25 ◦C by photon correlation spectroscopy (PCS) using a
alvern Nanosizer/Zetasizer® nano-ZS ZEN 3600 (Malvern Instru-
ents, USA). Each 20L sample was diluted in 10mL of ultrapure
ater. The analyses were performed three times to determine
ean values.
.5.2. Zeta potential measurement
The zeta potential was measured by electrophoretic mobility
sing Malvern Nanosizer/Zetasizer® nano-ZS ZEN 3600 (Malvern
nstruments, USA). All analyses were done in triplicate and each
0L sample was diluted in 10mL of an ultra-ﬁltered (0.22m)
olution of NaCl (1mM).
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not inﬂuence THD solubilization in the nanoemulsion internal
phase. Among the tested oils, THD presented the highest solubility
in castor oil (0.250mg/g). The mixture of Castor Oil/MCT (50:50),
which is reported to produce a decrease in the castor oil viscosity
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.5.3. THD assay
The THD content of the emulsions was assayed by the HPLC
ethod as previously described (Section 2.2). A ﬁxed amount of
he emulsion (0.500g) was diluted in a diluent solution composed
f acetonitrile:ammonium acetate buffer (pH 5.5; 10mM) (90:10,
/v) and 20L from the resulting solution was injected into the
PLC.
.5.4. Transmission electronic microscopy
One drop of THD nanoemulsion was placed on a carbon-coated
opper grid (200mesh) overlaid with 1% formwar in chloroform,
tained by 2.0% uranyl acetate aqueous solution and examined by
ransmission electronic microscopy using a JEM-1200 EXII instru-
ent (JEOL, Tokio, Japan).
.5.5. Viscosity
The rheological measurements were carried out in a AVS 350
iscometer (Schott-Geräte, Hofheim, Germany) equipped with a
apillary tube Ic (viscosimeter constant, k=0.035). The emulsion
7mL, adjusted to 25±0.1 ◦C) were poured into the ﬁlling tube
nd transferred to the capillary tube by gentle suction. The time
as recorded, in seconds, for the liquid to ﬂow from the upper to
he lower mark in the capillary tube. The analyses were done in
riplicate.
.6. Characterization of THD crystals
Drug crystals observed in the higher content formulation (THD
.05%, w/w) were collected at the bottom of the packing after
5 days of storage by ﬁltration in PVDF 0.4m pore size mem-
ranes and characterized by optical microscopy (Light microscopy
eiss Primo/Star Canon A650IS Digital Camera), fourier trans-
ormed infrared spectroscopy (FT-IR spectrophotometer Spectrum
X, Perkin–Elmer, MA, USA) over a range of 3800–500 cm−1 and X-
ay diffraction (Siemens D5000 diffractometer, Berlin, Germany)
nder the following conditions: CuK radiation, =1.5406 A˚, in a
ragg–Brentano –2 geometry, at 40kV and 20mA with a scan
ange between 8◦ and 40◦ and constant step, step size/time of
.02◦2/s.
.7. In vitro dissolutions studies
THD in vitro dissolution from the selected formulation (THD
.01P0.5) was assessed by the bulk-equilibrium reverse dialysis
ac technique (Benita and Levy, 1993; Chidambaram and Burgess,
999; Klang and Benita, 1998). For comparison purposes, an ace-
onitrile solution of THD in the same concentration was also
valuated.
The device consists of glass dissolution vessels inside an acrylic
ox water bath with temperature and magnetic stirrer controller.
he stirring was performed with Teﬂon coated magnetic stir bars.
The method consists of adding 10mL of the thalidomide
anoemulsion directly placed into the vessel containing 400mL
f ammonium acetate buffer 0.1mM. Dialysis bags (Spectrum
aboratories Inc., 2009) containing 5mL of buffer solution
n=3) were sealed at both ends with medicell clips (Spectrum
aboratories Inc., 2009) and placed at the bottom of the dissolu-
ion vessels. The dialysis bags were kept immersed in the same
uffer for 24h. The study was carried out at 37±0.5 ◦C using the
issolution device mentioned above under an agitation speed of
00 rpm. At predetermined time intervals (30, 40, 60, 120, 180 and
40min), 0.5mLof the solution inside of the dialysis bag and0.5mL
f the surrounding medium were collected and assayed by HPLC as
lready described.
F
oaceutical Sciences 42 (2011) 238–245
.8. Simulation of the in vivo proﬁle of the selected THD
anoemulsion
To study the applicability of the THD 0.01P0.5 formulation, its
ntravenous administration was simulated (Scientist version 3.0)
sing the open model of one compartment considering the admin-
stration of 25mg (250mL of formulation) given as continuous
nfusion during 2h, a ﬁrst order elimination (ke =0.143h−1) and
volume of distribution (Vd) of 20 L (Teo et al., 2004). The infusion
ate is in accordance with the recommendations for commercial
ipid emulsions with 10% of oil phase (Liposyn, 2010). For compar-
son purposes, the simulation of oral doses of 25mg and 200mg
ere also ﬁtted using the modiﬁed equation of compartimental
nalysis presented by Teo et al. (2004) (Eq. (2)), considering the fol-
owing parameters: faster rate constant (kfast) of 0.23h−1 for both
5mg and 200mg. Slower rate constant (kslow) of 0.639h−1 for a
oseof 25mgandof0.077h−1 for adoseof 200mg.Ake of0.143h−1
nd a Vd of 20 L for both doses.
.9. Statistical analysis
A statistical analysis of the differences between various treat-
ents was performed using analysis of variance (ANOVA) or a
aired Student’s t-test, as required. A 0.05 level of probability was
aken as the level of signiﬁcance.
. Results and discussion
.1. Determination of THD solubility in oils
The choice of the oil core is an important step on preformulation
tudies. The solubility of the drug usually drives the oil selection.
n this study, we employed oils commonly investigated in the
ormulation of parenteral emulsions (Klang and Benita, 1998;
loyd, 1999; Wanten and Calder, 2007) and that differ with respect
o the majoritary fatty acids: oleic acid (olive oil); ricinoleic acid
castor oil); linoleic acid (soybean oil); caprylic acid and capric
cid (MCT) (Rowe et al., 2006). The oil solubility of THD in the
elected oils is presented in Fig. 1. No signiﬁcant differences were
bserved between the solubility of the two polymorphic forms of
HD in all tested oils. Therefore, the polymorphic form used doesTriglycerides 50/50
Oil 
Alpha Thalidomide Beta Thalidomide
ig. 1. Thalidomide solubility in castor oil, MCT, oliva oil, soybean oil and castor
il/MCT 50/50.
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.05%) (*signiﬁcantly different (ANOVA (Tukey test, p≤0.05)).
nd interfacial tension of the oil phase (Jumaa and Muller, 1998,
999) was the second best alternative (0.200mg/g). The choice of
suitable oil phase was limited to castor oil.
.2. Preparation and characterization of THD nanoemulsions
After settling the oil core (castor oil, 10%, w/w), formulation
tudies were performed to deﬁne the emulsifying agents. Lecithins
re usually the best candidates as emulsiﬁers due to their current
se in commercial lipid emulsions. Based on preliminary manufac-
uring trials and according to previous literature (Shi et al., 2009;
ang et al., 2009), soybean lecithin was chosen and employed at
permitted concentration of 3.0% (w/w) (FDA, 2010). It produced
ilky, ﬂuid and apparently stable formulations at ﬁrst. Then, four
ormulations were prepared in triplicate in view to optimize THD
ontent (0.01%, 0.015%, 0.02% and 0.05%) (Table 1). Formulations
ere prepared with the -polymorph of THD.
For parenteral emulsions, the droplet size and polydispersity
ndex (PI) are important physicochemical parameters. Large parti-
le sizes are clinicallyunacceptabledue toemboli formation (Benita
nd Levy, 1993; Floyd, 1999). As can be observed in Fig. 2A, pho-
on correlation spectroscopy showed that at after seven days of
reparation, the average size of the emulsions was in the range of
12–196nm, which is a satisfactory range and classiﬁes the for-
ulations as indeed nanoemulsions (Benita and Levy, 1993; Floyd,
999; Tamilvanan, 2009). Fig. 2B also shows that after preparation,
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Fig. 3. Thalidomide content after 1, 7, 45 and 60 days of storagtial of formulations containing increasing amounts of THD (0.01, 0.015, 0.02 and
he formulations presented polydispersity indexes around 0.250.
olydispersity index (PI) characterizes the disperse systems with
espect to the deviation from the average size, and values up to
.250 are acceptable for parenteral emulsions (Müller et al., 2004).
The zeta potential is a stability indicative parameter in col-
oidal systems like submicron emulsions (Benita and Levy, 1993;
amilvanan and Benita, 2004; Tamilvanan, 2009). An emulsion
eaches the maximum stability when the zeta potential is greater
han 30mV (in module) (Buszello et al., 2000; Wang et al., 2006).
s can be observed in Fig. 2C, soybean lecithin with its negatively
harged phospholipids was able to produce a satisfactory nega-
ive surface potential for all formulations. Blank emulsions particle
ize and potential zeta were also evaluated (data not shown). The
esults showed no signiﬁcant differences when compared to the
HD emulsions.
All formulations kept its milky aspect with no sign of cream-
ng or ﬂocculation upon storage (4 ◦C). Nevertheless, at day 7,
crystallization process was capable of being seen in the 0.05%
HD formulation. The THD content of the nanoemulsions is shown
n Fig. 3. The formulations were monitored until the observation
f statistically signiﬁcant differences. Even though the values of
roplet size, polydispersity index (PI) and zeta potential remained
uite similar (data not shown), the higher content formulations
>0.02%, w/w) presented a large decrease of THD concentration
fter 7 days of preparation. At day 45, a signiﬁcant decrease of THD
ontent was observed in all but the 0.01% THD formulation. This
 *
*
Day 60Day 45
THD 0.02 THD 0.05
e (*signiﬁcantly different (ANOVA (Tukey test, p≤0.05)).
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istically signiﬁcant decrease in its content as compared with the
rst day, althoughno crystalwas visually observed.Nodegradation
f THD was observed by HPLC in these analyses.
.3. Characterization of THD crystallization
Optical microscope images of the crystals collected from the
igher content THD formulations (THD 0.05) (Fig. 4) revealed crys-
alswith a crystal habit different from that of the rawmaterial used
-polymorph). THD crystals presented a tabular prismatic form
ith awell-deﬁned surface (Fig. 4C), similar to that of-polymorph
Fig. 4A).
Both polymorphs have different FT-IR spectra, presenting char-
cteristic absorption bands. The -polymorphic form presents
tretching features around 3200 cm−1 (NH), 3100 cm−1(NH)
C
i
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eolymorph crystals (400× magniﬁcation); (B) photomicrographs of bulk THD -
(400× magniﬁcation); (D) FTIR spectra of thalidomide-polymorph,-polymorph
, -polymorph and nanoemulsion crystals.
nd 860 cm−1(CH), while -polymorph presents bands in
250 cm−1(NH) and 750 cm−1(CH) (Allen and Trotter, 1970;
eepmeyer et al., 1994; Lara-Ochoa et al., 2007; Carini et al., 2009).
he crystals collected from nanoemulsion presented characteristic
ands from-polymorph. THD crystallization as-polymorphwas
haracterized mainly by 3200 and 3100 cm−1 bands (Fig. 4D).
Diffractograms from all samples are shown in Fig. 4E. As can be
bserved, THD crystals from nanoemulsion clearly demonstrated
-polymorphic pattern which conﬁrms hypothesis of crystal
rowth as a different polymorph from that used for nanoemulsion
reparation (-THD) (Caira et al., 1994; Reepmeyer et al., 1994;
arini et al., 2009).
THD presents low solubility in oils, but this characteristic is not
nﬂuenced by THD polymorphism, as can be observed in Fig. 1.
n order to investigate whether THD polymorphism could inﬂu-
nce the nanoemulsion stability, a formulation was prepared using
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-polymorphic form (0.05%). The crystallization process was also
bserved and the collected crystals were characterized by opti-
al microscopy and FTIR. RXD was not performed due to the
mall amount of crystals. The crystals were characterized as -
olymorph as well (data not shown). Further studies are necessary
o determine whether the aqueous media is a favorable environ-
ent for THDcrystallizationas-formor somehowthemechanism
f crystal growth is inﬂuenced by the structure of the emulsion
Kogan et al., 2008).
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f formulations containing increasing amounts of polysorbate after 7 days (blank
olumns and squares) and 60 days (gray columns and diamond) of preparation
*signiﬁcantly different (Paired Samples (t-test, p≤0.05)).
rug transfer from interface to aqueous phase. Crystal formation
ould be a result of drug saturation, nucleation and ﬁnally drug
rystallization (Weiss, 2000; Han et al., 2004; Meldrum and Cölfen,
008; Giffard et al., 2009).
From the above results, the formulation containing 0.01% THD
nd 0.5% polysorbate 80 (THD0.01P0.5) was selected to be fur-
her evaluated. This formulation presented a viscosity of 2.9mPa s,
value acceptable for parenteral administration, i.e., below the
.9mPa s (Nielloud et al., 1996), and its morphology is illustrated
t Fig. 8. The image conﬁrms the results obtained by photon corre-
ation spectroscopy, showing a homogeneous distribution of small,
pherical globules around 200nm..5. THD release from optimized nanoemulsion
Preliminary tests were conducted in order to determine the
est test conditions. The conventional sac dialysis method was not
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Day 60
te. White columns: measures (±S.D.) after 7 days. Gray columns: measures (±S.D.)
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niﬁcantly different (ANOVA (Tukey test, p≤0.05)).
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fig. 8. Transmission electron photomicrograph of the THD nanoemulsion with
olysorbate 0.5%: A, 300k×, and B, 500k×; blank nanoemulsion with polysorbate
.5%: C, 300k×, and D, 300k×.
ossible to execute since less than 30% of THD dissolved after 24h
t 37 ◦C. In fact, the conventional dialysis technique may lead to
violation of sink conditions, since the membrane surface area
vailable for transport from the donor to the receiver phase is lim-
ted compared to the surface area available for transport from the
ispersed phase droplets to the continuous phase (Chidambaram
nd Burgess, 1999). Ammonium acetate 1mM pH 5.5 was chosen
s release medium (Schumacher et al., 1965; Yang et al., 2005) and
o signiﬁcant loss of THD was observed during the experiments.
he dissolution proﬁles of THD0.01P0.5 and THD0.01% acetonitrile
olution were assessed during 240min. Acetonitrile was found
ompatible with the membrane material (Spectrum Laboratories
nc., 2009), and was selected to prepare control THD solution.
As one can observe, the dissolution proﬁles were almost super-
mposable (Fig. 9), withmore than 80% of THDbeing dissolved after
h. Therefore, the dissolution of THD from the nanoemulsion is
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(f 200mg; thick line: 2-h i.v. infusion of 25mg, and thin line: oral dose of 25mg.
he following parameters were used in the simulations: 25mg i.v. (ke =0.143h−1;
d =20 L), 25mg oral [kfast = 0.23h−1; kslow =0.639h−1 (fast absorption); Vd=20L],
00mg oral [kfast = 0.23h−1; kslow =0.077h−1 (slow absorption); Vd=20L].
upposed to correspond to that of a THD solution, as expected for
n intravenous emulsion.
.6. Simulation of the pharmacokinetic proﬁle of the optimized
ormulation
Fig. 10 presents the linear simulated proﬁle of THD (dose of
5mg) after 2-h I.V. infusion of the THD 0.1mg/mL nanoemul-
ion. As can be observed, a maximum plasma concentration
Cmax) of 1.358mg/L was predicted at a dosage of 25mg (corre-
ponding to 250mL of the 0.01% THD nanoemulsion). This value
pproaches that of a traditional oral administration of 200mg THD
Cmax =1.9285mg/L), whose proﬁle has been formerly simulated
y Teo et al. (2004) as well. These ﬁndings corroborates that effec-
ive i.v. doses can be lower than the oral doses. THD is known
or presenting a ﬂip–ﬂop phenomenon for high oral doses, that
s, the elimination rate is faster than the absorption rate, and in
his case, the faster rate constant represents the elimination phase
Teo et al., 2004). This situation was taken into consideration in
he simulations, as proposed by Teo et al. (2004) and may explain
hy Bowcock et al. (2008) recently found that the dose of 25mg
as effective for the treatment ofmyeloma in elderly patientswith
negligible risk of neuropathy. It is worth noting that the oral
ose of 25mg is 8 times lower than that of 200mg, but leads to
Cmax (0.6917mg/L) that is only 2.8 times lower. Estimated Cmax
nd AUC for the i.v. proﬁle are twice higher than that of the same
ral dose (25mg). The calculated AUC of the oral 25mg, i.v. 25mg
nd oral 200mg were 5.5mg/L/h, 10.927mg/L/h and 38.5mg/L/h,
espectively.
Taken together, the simulated pharmacokinetics proﬁles may
uggest that even if THD loading to the nanoemulsions is quite lim-
ted (0.01%), such drug content might allow the administration of
feasible volume of parenteral emulsion leading to therapeutic
lasma concentrations. The THD nanoemulsion formulation could
venbemoreadvantageous for the treatmentofmedical conditions
here the intestinal absorption is impaired, as in GVHD.. Conclusions
Formulations prepared with castor oil (10%, w/w) lecithin
3.0%, w/w) and increasing amounts of THD (from 0.01 to 0.05%)
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resented droplet size, polydispersity index and zeta potential fea-
ible to i.v. administration. Nevertheless, drug crystallization was
bserved for the higher content formulation and it was demon-
trated that THD always precipitated in the -polymorphic form.
A signiﬁcant decrease of THD content was observed for the
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t a 0.5% (w/w) level. Higher polysorbate 80 concentrations led
o a signiﬁcant decrease on drug loading, possibly by facilitating
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